Article

Augmenting T helper cell immunity in cancer.

Department of Immunology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55906, USA.
Current Drug Targets - Immune Endocrine & Metabolic Disorders 01/2006; 5(4):365-71. DOI: 10.2174/156800805774913006
Source: PubMed

ABSTRACT Cancer specific immunity elicited with vaccines has traditionally focused on the activation of the CD8 cytolytic T lymphocyte (CTL) often involving direct stimulation of immunity using HLA-class I binding peptide epitopes. Recently it has become clear that activation of the CTL immune effector arm alone is insufficient to mediate an anticancer response. A major problem is that CD8 T cells alone can not be sustained without the concomitant activation of CD4 T helper (Th) cells. In fact, it is now widely recognized that the Th cell regulates nearly all aspects of the adaptive immune response. In addition, Th cells can recruit the innate immune system during immune augmentation. Therefore, the focus of the immune response in cancer has shifted away from activating CTL immunity alone to activating Th cell immunity alone or concurrently with CTL. Evidence suggests that activating the Th cell is sufficient to get a complete adaptive immune response because, once activated, the Th cell will elicit endogenous CD8 T cell and humoral immunity. In this review, we discuss the role of the Th cell in the adaptive immune response to cancer, how peptides that are capable of activation of Th cells are identified, and the clinical translation of newly identified candidate Th cell peptide epitopes to human cancer specific vaccines. Over the next decade, studies should begin to further define how we can manipulate the Th immune effector arm to achieve effective antitumor immunity.

1 Follower
 · 
131 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor-associated antigens resulting from aberrant glycosylation, such as the SialylTn carbohydrate antigen, are frequently over-expressed on cancer cells and provide potential targets for cancer vaccination. Immunization of Rhesus monkeys with SialylTn coupled to a highly immunogenic carrier molecule and formulated on aluminum hydroxide induced a strong immune response against the carrier protein but only a moderate IgM immune response against the SialylTn carbohydrate antigen. Co-formulation with QS-21 adjuvant dramatically enhanced the anti-SialylTn immune response and resulted in a SialylTn-specific IgG switch. The kinetics of the carbohydrate-specific IgG response correlated with a temporary release of cytokines such as IFNgamma, IL-2, IL-1beta, TNFalpha and GM-CSF which was measurable in the immune serum by xMAP Multiplex technology. Furthermore, tumor cell killing by activated natural killer cells was induced. These data demonstrate that immunization with a tumor-associated carbohydrate antigen in a highly immunogenic formulation results in a temporary release of type 1 cytokines which may be required for the induction of a specific IgG immune response against the carbohydrate antigen as well as for activation of effector cells against tumor cells.
    Cancer Immunology and Immunotherapy 07/2007; 56(6):863-73. DOI:10.1007/s00262-006-0231-x · 3.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The nontoxic B subunit of Shiga toxin (STxB) targets in vivo Ag to dendritic cells that preferentially express the glycolipid Gb(3) receptor. After administration of STxB chemically coupled to OVA (STxB-OVA) or E7, a polypeptide derived from HPV, in mice, we showed that the addition of alpha-galactosylceramide (alpha-GalCer) resulted in a dramatic improvement of the STxB Ag delivery system, as reflected by the more powerful and longer lasting CD8(+) T cell response observed even at very low dose of immunogen (50 ng). This synergy was not found with other adjuvants (CpG, poly(I:C), IFN-alpha) also known to promote dendritic cell maturation. With respect to the possible mechanism explaining this synergy, mice immunized with alpha-GalCer presented in vivo the OVA(257-264)/K(b) complex more significantly and for longer period than mice vaccinated with STxB alone or mixed with other adjuvants. To test whether this vaccine could break tolerance against self Ag, OVA transgenic mice were immunized with STxB-OVA alone or mixed with alpha-GalCer. Although no CTL induction was observed after immunization of OVA transgenic mice with STxB-OVA, tetramer assay clearly detected specific anti-OVA CD8(+) T cells in 8 of 11 mice immunized with STxB-OVA combined with alpha-GalCer. In addition, vaccination with STxB-OVA and alpha-GalCer conferred strong protection against a challenge with vaccinia virus encoding OVA with virus titers in the ovaries reduced by 5 log compared with nonimmunized mice. STxB combined with alpha-GalCer therefore appears as a promising vaccine strategy to more successfully establish protective CD8(+) T cell memory against intracellular pathogens and tumors.
    The Journal of Immunology 10/2007; 179(5):3371-9. DOI:10.4049/jimmunol.179.5.3371 · 5.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report here that HLA-DRbeta4*01 restricted MAGE-A3(161-175 )specific CD4(+) T cells from a healthy donor recognize a naturally processed epitope formed through the exogenous but not the endogenous pathway. However, the intensity of recognition of the native epitope by MAGE-A3(161-175 )specific CD4(+) T cells strongly depends on the antigen presenting cells and the amount of protein available for processing. EBV-transformed lymphoblastoid cells (LCLs) and melanoma cells engineered to express MAGE-A3 in the endosomal/lysosomal compartment were strongly recognized while autologous dendritic cells loaded with lysate from MAGE-A3 expressing cells were, although significantly, poorly recognized. To prove that the amount of antigen available for processing was a key factor determining the different response LCLs were sorted by MAGE-A3 expression. The response intensity correlated with the amount of MAGE-A3 expressed by the cells. Collectively, these results suggest that different antigen presenting cells with different amount of antigen available for processing as well as protease activity are important factors in determining the epitope repertoire produced in vivo, and therefore reliable tools should be used when testing recognition of native epitopes by peptide specific CD4(+) T cells.
    Cancer Immunology and Immunotherapy 03/2008; 57(2):207-15. DOI:10.1007/s00262-007-0364-6 · 3.94 Impact Factor

Preview

Download
1 Download
Available from